On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...

23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...

DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

Fertility agencies offering embryo selection for IVF and surrogacy have been accused of promoting eugenics and misleading ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

As the company restructures, it will pivot to selling genetic tests to consumers and using that data for research. Also: medicinal and tech advancements in cancer care; research monkeys roundup.

In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including ...

The familial trend, it turned out, was linked to a genetic mutation. That meant Bill might also be at risk for the disease.